PATENT CLAIM ANALYSIS

Application Number: 15978390
Application Type: Utility
Filing Date: 2018-05
Publication Date: 2018-10
Patent Classification: ["424", "135100"]

Abstract:
The present invention relates to bispecific constructs that specifically bind to immune effector cells and, simultaneously, to IL23R-carrying target cells, as well as nucleic acids, vectors, host cells, pharmaceutical compositions, and methods of production and use thereof, including such bispecific constructs for use in treating inflammatory and/or autoimmune diseases and/or cancer.

Claim (Index 1):
A method of treatment of an inflammatory and/or autoimmune disease or cancer comprising IL23R-expressing cells, comprising administering to a subject an effective amount of a bispecific construct comprising at least one first binding moiety and at least one second binding moiety, wherein said first binding moiety specifically binds to a first antigen present on a cytotoxic effector T (Tc) cell, wherein said first antigen is CD3, and said second binding moiety specifically binds to the IL23R present on the surface of the IL23R-expressing cells, and wherein said first binding moiety and said second binding moiety are antibody-based binding moieties.

Metadata:
- Claim Count in Document: 29.0
- Percentile: 93.0
- Lexical Diversity: 1.42857
- Patent Class: 424.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: True
- Related Applications: ['14889225', '15829783', '15604153', '15225107', '15829793']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.6641641140644705
- 35 USC 102 Novelty (BERT): 0.6620298382823222
- Combined Prediction Score: 0.6639506864862557
- Mean Citation Score: 362.187456
- Max Citation Score: 680.0639
- Similarity Product: 599.9416326296628

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test